Put Options

16 transactions
Quarter Operation Price Per put puts change puts Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$460.0 - $505.78 $46,000 - $50,578
-100 Reduced 0.29%
34,500 $16 Million
Q2 2024

Aug 13, 2024

SELL
$392.81 - $485.53 $3.77 Million - $4.66 Million
-9,600 Reduced 21.72%
34,600 $16.2 Million
Q1 2024

May 15, 2024

BUY
$407.69 - $446.08 $5.18 Million - $5.67 Million
12,700 Added 40.32%
44,200 $18.5 Million
Q4 2023

Feb 13, 2024

SELL
$343.0 - $410.68 $823,200 - $985,632
-2,400 Reduced 7.08%
31,500 $12.8 Million
Q3 2023

May 14, 2024

BUY
$338.18 - $362.46 $811,632 - $869,904
2,400 Added 7.62%
33,900 $11.8 Million
Q3 2023

Nov 14, 2023

SELL
$338.18 - $362.46 $6.53 Million - $7 Million
-19,300 Reduced 36.28%
33,900 $11.8 Million
Q2 2023

May 14, 2024

SELL
$314.42 - $351.91 $19.1 Million - $21.4 Million
-60,900 Reduced 53.37%
53,200 $18.7 Million
Q2 2023

Aug 14, 2023

SELL
$314.42 - $351.91 $19.1 Million - $21.4 Million
-60,900 Reduced 53.37%
53,200 $18.7 Million
Q1 2023

May 14, 2024

BUY
$283.23 - $323.1 $4.22 Million - $4.81 Million
14,900 Added 15.02%
114,100 $35.9 Million
Q1 2023

May 11, 2023

BUY
$283.23 - $323.1 $4.22 Million - $4.81 Million
14,900 Added 15.02%
114,100 $35.9 Million
Q4 2022

May 14, 2024

BUY
$285.76 - $321.48 $15.8 Million - $17.7 Million
55,200 Added 125.45%
99,200 $28.6 Million
Q4 2022

Feb 13, 2023

BUY
$285.76 - $321.48 $15.8 Million - $17.7 Million
55,200 Added 125.45%
99,200 $28.6 Million
Q3 2022

May 14, 2024

BUY
$273.83 - $305.53 $3.42 Million - $3.82 Million
12,500 Added 39.68%
44,000 $12.7 Million
Q3 2022

Nov 10, 2022

BUY
$273.83 - $305.53 $12 Million - $13.4 Million
44,000 New
44,000 $12.7 Million
Q4 2021

Feb 14, 2022

SELL
$177.01 - $223.45 $743,442 - $938,490
-4,200 Reduced 16.73%
20,900 $4.59 Million
Q3 2021

Nov 10, 2021

BUY
$181.39 - $202.99 $4.55 Million - $5.1 Million
25,100 New
25,100 $4.55 Million

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $105B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Goldman Sachs Group Inc Portfolio

Follow Goldman Sachs Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Goldman Sachs Group Inc with notifications on news.